Angiotensin-converting enzyme inhibition or angiotensin receptor blockage in hypertensive diabetics?

Current Hypertension Reports

Volumn 5, Issue 5, 2003, Pages 364-367

  Laverman, Gozewÿn ^a   Ruggenenti, Piero ^b   Remuzzi, Giuseppe ^b  

^a MARTINI HOSPITAL   (Netherlands)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET THERAPY; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MICROALBUMINURIA; MONOTHERAPY; REVIEW; SODIUM RESTRICTION; TREATMENT OUTCOME; URINARY EXCRETION; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; DRUG EFFECT; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 0642373672     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0080-3     Document Type: Review

References (39)

1. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59:8-13.
2. Fuller JH, Shipley MJ, Rose G, et al.: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res) 1983, 287:867-870.
3. The United States Renal Data System: USRDS 1997 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 1997.
4. Pastan S, Bailey J: Dialysis therapy. N Engl J Med 1998, 38:1428-1437.
5. Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res) 1982, 285:685-688.
6. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 1:1175-1179.
7. Hovind P, Rossing P, Tarnow L, et al.: Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 2001, 60:277-283.
8. Lievre M, Gueyffier F, Ekbom T, et al.: Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. Diabetes Care 2000, (Suppl 2):B65-B71.
9. Anderson S: Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metabab 1998, 24:406-411.
10. Ravid M, Brosh D, Levi Z, et al.: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998, 128:982-988.
11. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
12. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
14. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001, 134:370-379.
15. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672-678.
16. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
17. Remuzzi A, Ruggenenti P, Mosconi L, et al.: Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993, 6:36-43.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
19. Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601-606.
20. Ruggenenti P, Mosconi L, Sangalli F, et al.: Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int 1999, 55:984-994.
21. Parving HH, Hovind P, Rossing K, Andersen S: Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001, 10:515-522.
22. Brenner BM, Cooper ME, De Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
23. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
24. Laverman GD, Ruggenenti P, Remuzzi G: ACEi or ARB: which is better for cardiovascular and renal protection? J Am Soc Nephrol 2003, In press.
25. Laverman GD, De Zeeuw D, Navis GJ: Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? J Renin Angiotensin Aldost Syst 2002, 3:205-213.
26. Kincaid-Smith P, Fairley K, Packham D: Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002, 17:597-601.
27. Russo D, Pisani A, Balletta MM, et al.: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999, 33:851-856.
28. Russo D, Minutolo R, Pisani A, et al.: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001, 38:18-25.
29. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
30. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000, 321:1440-1444.
31. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001, 59:2282-2289.
32. Palla R, Panichi V, Finato V, et al.: Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994, 14:35-43.
33. Laverman GD, Navis G, Henning RH, et al.: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002, 62:1020-1025.
34. Ruggenenti P, Mise N, Pisoni R, et al.: Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003, 107:586-592.
35. Laverman GD, Henning RH, De Jong PE, et al.: Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001, 38:1381-1384.
36. Andersen S, Rossing P, Juhl TR, et al.: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002, 17:1413-1418.
37. Lonn EM, Shaishkoleslami R, Yi Q, et al.: Effects of ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. A substudy of HOPE [abstract]. J Am Coll Cardiol 2001, 37:165A.
38. Lonn E, Yusuf S, Dzavik V, et al.: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001, 103:919-925.
39. Laverman GD, Andersen S, Rossing P, et al.: Dose-dependent reduction of proteinuria by losartan does nor require reduction of blood pressure [abstract]. J Am Soc Nephrol 2002, 13:265A.